期刊
GENE THERAPY
卷 12, 期 8, 页码 647-654出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.gt.3302445
关键词
blood-brain barrier; osmotic disruption; virotherapy; herpes simplex virus; brain tumors
Delivery of viral vectors to tumors in the brain is a challenge, especially via systemic administration, which is key to targeting the invasive margins of malignant glioma and the multiple foci of metastatic disease. Like for other cancer therapeutics, the blood - brain barrier or even the blood tumor barrier significantly limits delivery and efficacy. Blood brain barrier disruption (BBBD) is one strategy for transiting the cerebrovasculature. G47D is a third-generation oncolytic replication-competent herpes simplex virus (HSV) vector, containing deletions of the gamma 34.5 and alpha 47 genes and an inactivating LacZ insertion in UL39 (ICP6). Intracarotid artery delivery of G47D after BBBD with 25% mannitol significantly extended the life of nude mice bearing intracerebral human MDA-MB-435 breast tumors, whereas, G47 Delta injection contralateral to the tumor, in the absence of mannitol or mannitol alone had no effect on survival. G47 Delta replication was extensive after BBBD, as visualized by X-gal staining. Staining of peripheral organs, lung and liver, was minimal and not altered by BBBD. This is the first demonstration of intracarotid arterial delivery of oncolytic HSV vectors and antitumor efficacy in a mouse model and opens the door to the use of mouse syngenic tumor models and transgenic/ knockout animals.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据